These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
198 related items for PubMed ID: 9368065
1. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome. Mellgren RL. J Biol Chem; 1997 Nov 21; 272(47):29899-903. PubMed ID: 9368065 [Abstract] [Full Text] [Related]
2. Inhibition of growth of human TE2 and C-33A cells by the cell-permeant calpain inhibitor benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone. Mellgren RL, Shaw E, Mericle MT. Exp Cell Res; 1994 Nov 21; 215(1):164-71. PubMed ID: 7957664 [Abstract] [Full Text] [Related]
3. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S. J Biochem; 1996 Mar 21; 119(3):572-6. PubMed ID: 8830056 [Abstract] [Full Text] [Related]
4. Comparison of the effect of calpain inhibitors on two extralysosomal proteinases: the multicatalytic proteinase complex and m-calpain. Figueiredo-Pereira ME, Banik N, Wilk S. J Neurochem; 1994 May 21; 62(5):1989-94. PubMed ID: 8158145 [Abstract] [Full Text] [Related]
5. Evidence for participation of a calpain-like cysteine protease in cell cycle progression through late G1 phase. Mellgren RL. Biochem Biophys Res Commun; 1997 Jul 30; 236(3):555-8. PubMed ID: 9245687 [Abstract] [Full Text] [Related]
6. Calpain involvement in calphostin C-induced apoptosis. Spinedi A, Oliverio S, Di Sano F, Piacentini M. Biochem Pharmacol; 1998 Dec 01; 56(11):1489-92. PubMed ID: 9827582 [Abstract] [Full Text] [Related]
7. Characterization of the active site of human multicatalytic proteinase. Mason RW. Biochem J; 1990 Jan 15; 265(2):479-84. PubMed ID: 2302179 [Abstract] [Full Text] [Related]
9. Evidence for the participation of the proteasome and calpain in early phases of muscle cell differentiation. Ueda Y, Wang MC, Ou BR, Huang J, Elce J, Tanaka K, Ichihara A, Forsberg NE. Int J Biochem Cell Biol; 1998 Jun 01; 30(6):679-94. PubMed ID: 9695025 [Abstract] [Full Text] [Related]
10. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Zhang W, Lu Q, Xie ZJ, Mellgren RL. Oncogene; 1997 Jan 23; 14(3):255-63. PubMed ID: 9018111 [Abstract] [Full Text] [Related]
11. Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Wagenknecht B, Hermisson M, Eitel K, Weller M. Cell Physiol Biochem; 1999 Jan 23; 9(3):117-25. PubMed ID: 10494025 [Abstract] [Full Text] [Related]
12. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Zhang XM, Lin H, Chen C, Chen BD. Biochem J; 1999 May 15; 340 ( Pt 1)(Pt 1):127-33. PubMed ID: 10229667 [Abstract] [Full Text] [Related]
13. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. Bush KT, Goldberg AL, Nigam SK. J Biol Chem; 1997 Apr 04; 272(14):9086-92. PubMed ID: 9083035 [Abstract] [Full Text] [Related]
14. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. An WG, Hwang SG, Trepel JB, Blagosklonny MV. Leukemia; 2000 Jul 04; 14(7):1276-83. PubMed ID: 10914553 [Abstract] [Full Text] [Related]
15. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Orlowski M, Cardozo C, Michaud C. Biochemistry; 1993 Feb 16; 32(6):1563-72. PubMed ID: 8431436 [Abstract] [Full Text] [Related]
16. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. Han Y, Weinman S, Boldogh I, Walker RK, Brasier AR. J Biol Chem; 1999 Jan 08; 274(2):787-94. PubMed ID: 9873017 [Abstract] [Full Text] [Related]
17. Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone. McCormack TA, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Plamondon L, Stein RL, Dick LR. Biochemistry; 1998 May 26; 37(21):7792-800. PubMed ID: 9601040 [Abstract] [Full Text] [Related]
18. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Proc Natl Acad Sci U S A; 1999 Aug 31; 96(18):10403-8. PubMed ID: 10468620 [Abstract] [Full Text] [Related]
19. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. Schubert U, Antón LC, Bacík I, Cox JH, Bour S, Bennink JR, Orlowski M, Strebel K, Yewdell JW. J Virol; 1998 Mar 31; 72(3):2280-8. PubMed ID: 9499087 [Abstract] [Full Text] [Related]
20. Degradation of p21cip1 in cells productively infected with human cytomegalovirus. Chen Z, Knutson E, Kurosky A, Albrecht T. J Virol; 2001 Apr 31; 75(8):3613-25. PubMed ID: 11264351 [Abstract] [Full Text] [Related] Page: [Next] [New Search]